<SEC-DOCUMENT>0001193125-22-289487.txt : 20221121
<SEC-HEADER>0001193125-22-289487.hdr.sgml : 20221121
<ACCEPTANCE-DATETIME>20221121070055
ACCESSION NUMBER:		0001193125-22-289487
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20221118
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221121
DATE AS OF CHANGE:		20221121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16174
		FILM NUMBER:		221403462

	BUSINESS ADDRESS:	
		STREET 1:		5 BAZEL ST
		STREET 2:		P O B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
		BUSINESS PHONE:		9729267267

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		5 BAZEL ST PO B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d284218d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:teva="http://www.tevapharm.com/20221118" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2022-11-18_to_2022-11-18">TEVA PHARMACEUTICAL INDUSTRIES LTD</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityTaxIdentificationNumber" name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-11-18_to_2022-11-18">00-0000000</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-11-18_to_2022-11-18">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-11-18_to_2022-11-18">0000818686</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="teva-20221118.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-11-18_to_2022-11-18"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-18</xbrli:startDate> <xbrli:endDate>2022-11-18</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-11-18_to_2022-11-18">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-11-18_to_2022-11-18" format="ixt:datemonthdayyearen">November 18, 2022</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-11-18_to_2022-11-18" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-11-18_to_2022-11-18">001-16174</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"> <span style=" -sec-ix-hidden:Hidden_dei_EntityTaxIdentificationNumber">Not Applicable</span> </span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification Number)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:99%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-11-18_to_2022-11-18">124 Dvora Hanevi&#8217;a Street</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-11-18_to_2022-11-18">Tel Aviv</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-11-18_to_2022-11-18">6944020</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="duration_2022-11-18_to_2022-11-18" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices, including Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">+<ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-11-18_to_2022-11-18">972</ix:nonNumeric>-<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-11-18_to_2022-11-18">3-914-8213</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s Telephone Number, including Area Code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Copies of communications to: </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-11-18_to_2022-11-18" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-11-18_to_2022-11-18" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-11-18_to_2022-11-18" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-11-18_to_2022-11-18" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-11-18_to_2022-11-18">American Depositary Shares, each representing one Ordinary Share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-11-18_to_2022-11-18">TEVA</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-11-18_to_2022-11-18" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging Growth Company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-11-18_to_2022-11-18" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">ITEM&#160;5.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;21, 2022, Teva Pharmaceutical Industries Ltd. (the &#8220;Company&#8221;) announced that its Board of Directors had appointed Richard Francis to become the Company&#8217;s President and Chief Executive Officer, effective January&#160;1, 2023. In order to facilitate an orderly transition, K&#229;re Schultz and the Company&#8217;s Board of Directors have mutually agreed that Mr.&#160;Schultz will retire from his current positions as President and Chief Executive Officer, and a member of the Board of Directors, effective December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Francis, age 54, is a seasoned pharmaceutical executive bringing over two decades of experience to the Company, including five years as Chief Executive Officer of Sandoz and a member of the Novartis Executive Team from 2014 to 2019. Prior to his role at Sandoz, Mr.&#160;Francis was a senior executive at Biogen for 13 years where he held a number of senior roles, including leading the U.S. business. He also oversaw the successful launch of Tecfidera<sup style="font-size:75%; vertical-align:top">&#174;</sup> in 2013. Mr.&#160;Francis has served as the CEO of Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, since 2021, and as CEO of Forcefield Therapeutics, a pioneer of <span style="white-space:nowrap"><span style="white-space:nowrap">best-in-class</span></span> therapeutics to protect heart function, since 2021. He has also served as an operating partner for Syncona Investment Management Limited since 2021. Mr.&#160;Francis also serves as a member of the board of directors of Mettler-Toledo International Inc. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Francis and the Company have entered into an employment agreement (the &#8220;Employment Agreement&#8221;), which provides for an initial employment term of three years, subject to automatic renewal for successive <span style="white-space:nowrap">one-year</span> periods unless either party gives at least six months advance notice of <span style="white-space:nowrap">non-renewal</span> or termination. Under the Employment Agreement, Mr.&#160;Francis will receive an annual base salary of USD $1.6&#160;million, a target annual bonus opportunity equal to 150% of his annual base salary (and a maximum opportunity of 200% of his annual base salary), annual equity incentives with a total target grant date fair value of USD $9&#160;million, 70% of which will be in the form of performance stock units (&#8220;PSUs&#8221;) and 30% in the form of restricted stock units (&#8220;RSUs&#8221;), and the same employee benefits as are provided to similarly situated senior executives of the Company. Upon commencing employment, in light of forfeited compensation opportunities at his prior employer and to incentivize him to join the Company, Mr.&#160;Francis will also receive (a)&#160;the following <span style="white-space:nowrap">sign-on</span> equity awards: (i)&#160;an RSU award with a grant date fair value of USD $5&#160;million, which will vest in equal installments on the first, second and third anniversaries of the grant date, subject to his continued employment through the applicable vesting dates; and (ii)&#160;a PSU award with a target grant date fair value of USD $5&#160;million, which will be earned based on the achievement of stretch performance goals to be established by the Human Resources&#160;&amp; Compensation Committee of the Board prior to the 2023 annual meeting of shareholders, and (b)&#160;a <span style="white-space:nowrap">sign-on</span> cash award of USD $5&#160;million, which will vest and be paid in three installments, with the first installment, equal to $1,500,000, to be paid on the first business day following the date that Mr.&#160;Francis commences employment with the Company (the &#8220;Effective Date&#8221;), the second installment, equal to $1,500,000, to be paid on the first business day following the first anniversary of the Effective Date, and the third installment, equal to $2,000,000, to be paid on the first business day following the third anniversary of the Effective Date, in each case subject to his continued employment through the applicable vesting date. In connection with rendering services from the Company&#8217;s principal offices in Israel, Mr.&#160;Francis will also receive certain housing and travel reimbursements, annual allowance for financial and tax advisory fees, and certain other relocation benefits in accordance with the Company&#8217;s policies. The Employment Agreement also provides for a <span style="white-space:nowrap">one-time</span> legal fee reimbursement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Mr.&#160;Francis&#8217;s employment were terminated by the Company without &#8220;cause&#8221; or by him for &#8220;good reason&#8221; (each term as defined in the Employment Agreement), he would be entitled to, as of the date of termination: (a)&#160;cash severance equal to two times his annual base salary; (b)&#160;vesting (on the later of the date of termination and the first anniversary of the grant date) of any portion of the <span style="white-space:nowrap">sign-on</span> RSU award that is unvested; (c)&#160;vesting of the portion of the <span style="white-space:nowrap">sign-on</span> PSU award that is earned based on actual performance at the end of the applicable performance period; (d)&#160;vesting of any portion of the <span style="white-space:nowrap">sign-on</span> cash award that is unvested; (e)&#160;if Mr.&#160;Francis has been employed by the Company for at least 12 months, a prorated annual bonus for the year of termination, determined based on actual performance; and (f)&#160;if the date of termination occurs within the first year following a change in control of the Company, an additional cash severance payment equal to his annual base salary. In addition, in consideration for Mr.&#160;Francis&#8217;s compliance with certain restrictive covenants including noncompetition covenants, Mr.&#160;Francis shall be entitled to payment of 12 months of his base salary, payable in 12 equal monthly installments following the date of termination for any reason other than due to his death or termination for cause by the Company. All severance benefits (other than any portion required under applicable law) and the noncompete payment are subject to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Mr.&#160;Francis&#8217;s execution of a release of claims in favor of the Company and compliance with the restrictive covenants included in the Employment Agreement, which consist of a <span style="white-space:nowrap">12-month</span> post-termination noncompetition covenant, a <span style="white-space:nowrap">24-month</span> post-termination nonsolicitation covenant, a perpetual confidentiality covenant and a <span style="white-space:nowrap">10-year</span> post-termination nondisparagement covenant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no arrangements or understandings between Mr.&#160;Francis and any other person pursuant to which Mr.&#160;Francis was appointed to serve as President and Chief Executive Officer of the Company. There are no family relationships between Mr.&#160;Francis and any director or executive officer of the Company, and Mr.&#160;Francis has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of <span style="white-space:nowrap">Regulation&#160;S-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the leadership transition, Mr.&#160;Schultz and the Company entered into a letter agreement summarizing the terms of his departure, including that he will continue to serve as President and Chief Executive Officer and a member of the Board of Directors through December&#160;31, 2022 and will thereafter be placed on garden leave until the expiration of his contractual notice period on February&#160;19, 2023. During the garden leave period, Mr.&#160;Schultz has agreed to be available to assist with the transition. Mr.&#160;Schultz&#8217;s termination of employment will be treated as a termination without cause under his employment agreement with the Company, which will entitle him to the applicable payments and benefits specified in his employment agreement during his notice period and upon termination of employment, subject, to the extent applicable, to his execution and <span style="white-space:nowrap">non-revocation</span> of a release of claims in favor of the Company and compliance with the restrictive covenants set forth in his employment agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the Company&#8217;s press release relating to the leadership transition is attached to this Current Report on Form <span style="white-space:nowrap">8-K</span> as Exhibit&#160;99.1. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">ITEM&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit&#160;No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d284218dex991.htm">Press Release, dated November&#160;21, 2022 </a></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: November&#160;21, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eli Kalif</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Eli Kalif</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President, Chief Financial Officer</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d284218dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g284218g01a02.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g284218g80o96.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Teva Announces Appointment of Richard Francis as President and CEO </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>K&aring;re Schultz to Retire After a Transformative Five-Year Tenure Setting the Stage for an Exciting Future </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TEL AVIV, Israel &#150; November</B><B></B><B>&nbsp;21, 2022 &#150;</B><B></B>&nbsp;Teva Pharmaceutical Industries Ltd. (&#147;Teva&#148; or the
&#147;Company&#148;) (NYSE and TASE: TEVA), today announced that the Company&#146;s Board of Directors has appointed Richard Francis as President and Chief Executive Officer, effective January&nbsp;1, 2023. In order to facilitate an orderly
transition, K&aring;re Schultz and the Teva Board of Directors have mutually agreed that Mr.&nbsp;Schultz will retire from his current position as Chief Executive Officer, effective December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Francis is a seasoned pharmaceutical executive bringing more than two and a half decades of experience to Teva, including five years as Chief
Executive Officer of Sandoz and a member of the Novartis Executive Team. Prior to his role at Sandoz, Mr.&nbsp;Francis was a senior executive at Biogen for 13 years where he held a number of senior roles, including leading the U.S. business. He also
oversaw the successful launch of Tecfidera<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> in 2013. Mr.&nbsp;Francis is currently the CEO of Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment
of kidney diseases, and CEO of Forcefield Therapeutics, a pioneer of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapeutics to protect heart function. He is also an operating partner for Syncona
Investment Management Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;It has been a great privilege to serve Teva as its CEO since 2017, and to work with our dedicated and talented team
to improve the lives of patients,&#148; said Mr.&nbsp;Schultz. &#147;We have positioned Teva as a leader in both our specialty and generics businesses, built a strong financial and operational foundation and enhanced our portfolio and pipeline. This
is the right time for a transition, and Richard&#146;s proven track record in the industry makes him the right person to serve as Teva&#146;s next CEO.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;On behalf of the entire Board, I would like to thank K&aring;re for his dedication and contributions to Teva over the last five years,&#148; said
Dr.&nbsp;Sol&nbsp;J. Barer, Chairman of Teva&#146;s Board of Directors. &#147;Under K&aring;re&#146;s leadership, we have stabilized the business and undergone a significant operational transformation across our international footprint. The Company
is now well positioned for an exciting future and, by leveraging Richard&#146;s compelling track record of growing businesses in the life sciences, biologics and generic drug sectors, his entrepreneurial and pragmatic leadership style and emphasis
on a collaborative and innovative culture, the Board and I are confident that Teva will build on this solid foundation. As a global enterprise, we look forward to furthering our mission to provide much needed medicines to even more patients around
the world under Richard&#146;s leadership. The Board is delighted to have found the ideal leader for the next phase in Teva&#146;s exciting journey to return to growth and leadership.&#148; </P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>IR Contacts</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ran Meir</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Yael Ashman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(267) <FONT STYLE="white-space:nowrap">468-4072</FONT></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">972 (3) <FONT STYLE="white-space:nowrap">914-8262</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g284218g63n72.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PR Contacts</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kelley Dougherty</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Eden Klein</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(973)-832-2810</FONT></FONT></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">972 (3) 906 2645</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g284218g01a02.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g284218g80o96.jpg" ALT="LOGO">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I have long been impressed with the value Teva provides to patients globally and I am honored to take
on the role of leading this extraordinary company into the future,&#148; said Mr.&nbsp;Francis. &#147;I look forward to leveraging my background and years of pharmaceutical experience to build on Teva&#146;s strong fundamentals and to write the next
exciting chapter for Teva, focusing on building a solid pathway to deliver long-term growth. I continue to see a bright future ahead for the Company and look forward to working closely with the Board, management team and talented employees to
continue driving value creation for patients, employees, shareholders and other stakeholders.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Richard Francis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard Francis is an operating Partner at Syncona, which focuses on founding, building and funding healthcare companies. Mr.&nbsp;Francis is the Chief
Executive Officer of Syncona&#146;s portfolio companies, Purespring Therapeutics, one of the first AAV gene therapy companies focused on the kidney globally, and Forcefield Therapeutics, a pioneer of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapeutics to retain heart function via protection of cardiomyocytes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to his current
roles, Mr.&nbsp;Francis spent five years as the Chief Executive Officer of Sandoz and a member of the Novartis Executive Team. During Mr.&nbsp;Francis&#146; time at Sandoz, he developed a transformative strategy to reshape the business by focusing
the organization on key geographies, reshaping the portfolio and targeting efficiencies to drive growth and margin improvement. Mr.&nbsp;Francis held various leadership roles over a <FONT STYLE="white-space:nowrap">13-year</FONT> tenure at Biogen,
including Senior Vice President of U.S. Commercial, Vice President / Senior Vice President of Global Commercial Strategy, Managing Director of Canada and Managing Director of the UK and Ireland. During his time at Biogen, Mr.&nbsp;Francis oversaw
the growth of the U.S. Commercial business, driven by a strategic focus on commercial excellence. To that end, at Biogen, Mr.&nbsp;Francis led the successful launch of Tecfidera<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> in 2013.
Earlier in his career, Mr.&nbsp;Francis worked at Sanofi and Wyeth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Francis holds a Bachelor of Arts in Economics from The Manchester
Metropolitan University. </P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>IR Contacts</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ran Meir</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Yael Ashman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(267) <FONT STYLE="white-space:nowrap">468-4072</FONT></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">972 (3) <FONT STYLE="white-space:nowrap">914-8262</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g284218g63n72.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PR Contacts</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kelley Dougherty</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Eden Klein</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(973)-832-2810</FONT></FONT></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">972 (3) 906 2645</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g284218g01a02.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g284218g80o96.jpg" ALT="LOGO">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Teva</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people&#146;s lives for more than a century.
We are a global leader in generic, biosimilar and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200&nbsp;million people around the world take a Teva medicine every day, and are served
by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and
biopharmaceutical products. Learn more at <U>www.tevapharm.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on
management&#146;s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or
implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as &#147;should,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;target,&#148; &#147;may,&#148;
&#147;project,&#148; &#147;guidance,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe&#148; and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.
Important factors that could cause or contribute to such differences include risks relating to our ability to attract, hire and retain highly skilled personnel; our ability to successfully compete in the marketplace, including our ability to develop
and commercialize biopharmaceutical products, competition for our specialty products, including AUSTEDO<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, AJOVY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;and COPAXONE<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>; our ability to achieve expected results from investments in our product pipeline, our ability to develop and commercialize additional pharmaceutical products, and the effectiveness of our
patents and other measures to protect our intellectual property rights; our substantial indebtedness; our business and operations in general; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays
in governmental processing time due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; compliance, regulatory and litigation matters, including failure to comply with complex legal and regulatory environments; other financial and
economic risks; and other factors discussed in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the third quarter of 2022 and in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2021, including in the section captioned &#147;Risk Factors.&#148; Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other
information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>IR Contacts</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ran Meir</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Yael Ashman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(267) <FONT STYLE="white-space:nowrap">468-4072</FONT></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">972 (3) <FONT STYLE="white-space:nowrap">914-8262</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g284218g63n72.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PR Contacts</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kelley Dougherty</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Eden Klein</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(973)-832-2810</FONT></FONT></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">972 (3) 906 2645</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>teva-20221118.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 11/21/2022 4:39:10 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:teva="http://www.tevapharm.com/20221118"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.tevapharm.com/20221118"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="teva-20221118_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="teva-20221118_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>teva-20221118_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 11/21/2022 4:39:11 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>teva-20221118_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 11/21/2022 4:39:11 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="teva-20221118.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g284218g01a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g284218g01a02.jpg
M_]C_X02#17AI9@  34T *@    @ # $   ,    !#;0   $!  ,    !";
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   ?    M $R  (    4    TX=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P(#(R+C4@*%=I;F1O=W,I #(P
M,C(Z,3$Z,C$@,#@Z,#DZ,S$    $D   !P    0P,C,QH $  P    '__P
MH ( !     $   !KH , !     $    F          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!RP           "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 2P    !  $!+     $  3A"24T$
M)@      #@             _@   .$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M1P    8              "8   !K    "0!T &4 =@!A "  ; !O &< ;P
M  $                          0              :P   "8
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   "8     4F=H
M=&QO;F<   !K    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<    F     %)G:'1L;VYG    :P    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ "0 9 P$B  (1 0,1 ?_=  0
M O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MMT[_ (G*_P#/3E!-]'M?X'_5/D_\-X_^?[B?5_6_;_WC_]D .$))300A
M  !7     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __" !$( "8
M:P,!$0 "$0$#$0'_Q #4   !! ,! 0             *!P@)"P !!@,$ 0 "
M @,! 0$            '" 4&  $$ @,)$  ! P0!!  & @,        &! 4'
M @,("0$ $!,5118V%Q@*2#D@%!H1   & 0(% 08#!P4       $" P0%!@<1
M"  2$Q05%A A,2(D%R,)&6$R,R48B,FQ=29WMQ(  @(! P(#! 8%"@<
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MDR,J[RBX,%4"EG@^PMHLC6)CZ+:<ZPO=B6BL.=2:V7<H)]I2" ?PP/9U^_\
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M>_\ %*^*R;*6&X,3#L.X*JS!VGN"HUD1TN+RE]MW&EH*M+-7K!*S+:?@[0(
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@QO2_5']4>I.U^Q?F? ^?_P"-=+MO(^5^H[?Q?UW'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g284218g63n72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g284218g63n72.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MJ/J]/L'U>EV#_A!_#G_0._\ (TG_ ,51]7I]@^KTNP?\(/X<_P"@=_Y&D_\
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< % !0 4 % !0 4 % !0 4 % !0 4 % !0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g284218g80o96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g284218g80o96.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M"QZTACQ0,Z3PM_R]_P# /ZUZ.!^U\OU.BEU.BKT38* "@ H * "@ H * "@
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MIRH-(T1TOA;_ )>_^ ?UKT<#]KY?J=%+J=%7HFP4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!!>6L=Y:26\@^5QCZ'UJ)P4XN+)E%25F>
M=SP/;3R0R##H<&O#E%Q=F<#5G88!4@21G!Q2&CJ/"O\ R]_\ _K7HX'[7R_4
MZJ74Z*O1-@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M Y;Q5889+Y!U^1_Z&O.QE/::.:M'[1S@%>><XHI#.H\*'(N_^ ?UKT<#]KY?
MJ=-'J='7HFX4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 0W=LEW:2P/]UUQ]*B<%.+BQ25U8\]DB:&5XG&'0E37A-.+LSAM;00"I Z7
MPH,?:_\ @']:]' _:^7ZG11ZG25Z)N% !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!R7B:S\J]2X48648/^\/_ *U>5C*?+/F74YJL
M;.YB@8KB,CI/"O'VO_@']:]' _:^7ZF]'J='7HFX4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % &?K5K]JTR50,NGSK]17/B(<]-HB
M:O$XD5XIR'1^%?\ E[_X!_6O1P/VOE^IO2ZG1UZ)N% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 $<8H X/4+;[+J$T.,!6ROT/2O
M!JPY)N)R25G8VO"W'VO_ (!_6NW _:^7ZFM+J=%7HFP4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!S/B:WVSPW '##:?J.E>9C
M86:D855K<D\+?\O?_ /ZU6!^U\OU'2ZG15Z)L% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 9NNP>=I4A YC(<?A_\ 6KFQ4>:F
M_(BHKQ,_PM_R]_\  /ZUSX'[7R_4BEU.BKT38* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H 9+&)87C/1E(I25TT)ZF%X94H]XA
MZJ5!_P#'JX,$K.2_KJ94M+G05Z!L% !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % &5ID7DZIJ2XP"R,/QR:Y:,>6I->AG%6DS5
MKJ- H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
>H B2!$N))AG=( #Z<9_QJ5%*3EW%:SN2U0PH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139631326843456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 18, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TEVA PHARMACEUTICAL INDUSTRIES LTD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000818686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 18,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-16174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">124 Dvora Hanevi&#8217;a Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6944020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3-914-8213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">American Depositary Shares, each representing one Ordinary Share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TEVA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d284218d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="teva-20221118.xsd" xlink:type="simple"/>
    <context id="duration_2022-11-18_to_2022-11-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2022-11-18</startDate>
            <endDate>2022-11-18</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2022-11-18_to_2022-11-18"
      id="Hidden_dei_EntityRegistrantName">TEVA PHARMACEUTICAL INDUSTRIES LTD</dei:EntityRegistrantName>
    <dei:EntityTaxIdentificationNumber
      contextRef="duration_2022-11-18_to_2022-11-18"
      id="Hidden_dei_EntityTaxIdentificationNumber">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:AmendmentFlag contextRef="duration_2022-11-18_to_2022-11-18">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-11-18_to_2022-11-18"
      id="Hidden_dei_EntityCentralIndexKey">0000818686</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-11-18_to_2022-11-18">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-11-18_to_2022-11-18">2022-11-18</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-11-18_to_2022-11-18">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-11-18_to_2022-11-18">001-16174</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-11-18_to_2022-11-18">124 Dvora Hanevi&#x2019;a Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-11-18_to_2022-11-18">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-11-18_to_2022-11-18">6944020</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="duration_2022-11-18_to_2022-11-18">IL</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="duration_2022-11-18_to_2022-11-18">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-11-18_to_2022-11-18">3-914-8213</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-11-18_to_2022-11-18">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-11-18_to_2022-11-18">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-11-18_to_2022-11-18">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-11-18_to_2022-11-18">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-11-18_to_2022-11-18">American Depositary Shares, each representing one Ordinary Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-11-18_to_2022-11-18">TEVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-11-18_to_2022-11-18">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-11-18_to_2022-11-18">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !LX=56RWAH4[0   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !LX
M=5697)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ &SAU54L^67ID!   MQ   !@
M ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !LX
M=56?H!OPL0(  .(,   -              "  :8,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ &SAU59>*NQS     $P(   L              ( !@@\
M %]R96QS+RYR96QS4$L! A0#%     @ &SAU51PX9>H_ 0  / (   \
M         ( !:Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !LX=54D
M'INBK0   /@!   :              "  =<1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( !LX=55ED'F2&0$  ,\#   3
M      "  ;P2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
'  84      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d284218d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  d284218d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="d284218d8k.htm">d284218d8k.htm</File>
    <File>d284218dex991.htm</File>
    <File>teva-20221118.xsd</File>
    <File>teva-20221118_lab.xml</File>
    <File>teva-20221118_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d284218d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d284218d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "teva-20221118_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "teva-20221118_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "teva-20221118.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 4
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "teva",
   "nsuri": "http://www.tevapharm.com/20221118",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284218d8k.htm",
      "contextRef": "duration_2022-11-18_to_2022-11-18",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d284218d8k.htm",
      "contextRef": "duration_2022-11-18_to_2022-11-18",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-22-289487-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-289487-xbrl.zip
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MB2CXB^M;:O)%RR;ZN(F@G'SGF$?AF*W(.&BAZ][E#;ON77VZOGE^G7.5*)U
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M4*53 (3P])$'W)@Z]D%.)&KWX@0+%,VG(I&;%Z9!JJF\W$X/V4<1QSXXL3?
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M=;+*RS\Q>9X59VJV,I,GO6QEYD\4;G7N";>.FX/0F\$3B$G]D_\'4$L#!!0
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M$C^CN/U-C6FW=9I5?0:NX.=+VFF6A$7 +$_] *OO$$A5DD;5"6KN%2 *HNI
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M(65=M$,Q-G%EQNB<XIN/]5."JS$%X!=CET#^/B[Q7*3VZ0P6O]9&"=NXOU(
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MVDOYA1M]9'YG1/X2S7YS@G[E/U!+ P04    "  ;.'55AH4E-*X$  !G*@
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MB'VQ3_MAR=]02P$"% ,4    "  ;.'55(J*0<_$8  #/B   #@
M    @ $     9#(X-#(Q.&0X:RYH=&U02P$"% ,4    "  ;.'55DD3U>Z42
M   45P  $0              @ $=&0  9#(X-#(Q.&1E>#DY,2YH=&U02P$"
M% ,4    "  ;.'55BCD[?SL#  !0"P  $0              @ 'Q*P  =&5V
M82TR,#(R,3$Q."YX<V102P$"% ,4    "  ;.'55L)R@P4\&  ![0P  %0
M            @ %;+P  =&5V82TR,#(R,3$Q.%]L86(N>&UL4$L! A0#%
M  @ &SAU58:%)32N!   9RH  !4              ( !W34  '1E=F$M,C R
C,C$Q,3A?<')E+GAM;%!+!08     !0 % $ !  "^.@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
